Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I gave up on this company a long time ago; but Stockhouse put this up as a news release on their web site. Sorry for not paying closer attention before I copied and pasted it on this site.
Convey Announces New Relationships with ControlScan and Comdata Corporation
MINNEAPOLIS, Sept. 27, 2011 /PRNewswire via COMTEX News Network/ --
Convey Compliance Systems has entered into two new relationships to expand availability of its tax information reporting solutions to transportation and payment solutions markets.
Convey is excited to be working with Comdata, a leader in electronic payment innovation, and ControlScan, which offers compliance solutions to the Payment Card Industry (PCI), because of their unique positions in their respective markets. The partnerships will introduce Convey's tax information reporting solutions to businesses that have been asking for more help with their tax reporting obligations.
Troy Thibodeau, Executive Vice President at Convey, sees great potential in opening up Convey to two new industries facing a maze of tax reporting regulations: "Through our new partner relationships, more businesses will now be able to save time and money through automating information reporting compliance activities," he said. "These businesses will be able to rest assured they are prepared to handle a constantly changing set of tax reporting regulatory changes with efficiency."
For ControlScan's clients, merchant acquirers, tax regulation requirements have become even more pressing in 2011. Starting this year, all those who handle card payment transfers must adhere to the IRS' "Section 6050W" code that requires that 3rd party settled payments to merchants be reported, significantly increasing the tax information reporting demands on acquirers.
"Our partnership with Convey, a 25 year old company with staff dedicated 100 percent to tax compliance and reporting, greatly reduces the impact of tax regulation on our acquirer customers," said Joan Herbig, CEO, ControlScan. "Paired with our guidance through PCI compliance and security issues, acquirers and the merchants they serve can focus more on business and services and less on the ever-changing and increasingly-demanding regulatory landscape."
Comdata will be referring business to Convey from the accounts payable departments of companies it serves within fleet, construction, retail, hospitality and other industries. "Comdata strives to help our customers maximize efficiency. Extending Convey's solutions for tax information reporting is another value-added benefit we are excited to offer," said Randy Morgan, executive vice president of sales and marketing for Comdata.
About Convey
Convey provides tax information reporting services and software to businesses to make IRS compliance clear and uncomplicated. With Convey's flexible, scalable software and the guidance and focused experience of its service teams, Convey's clients - from small companies to nearly half of the Fortune 500 - can be assured that they're complying with IRS regulations and reporting financial transactions efficiently and correctly. Convey reduces risk, improves bottom lines, and provides the clearest path to compliance. For more information, visit www.convey.com.
About Comdata Corporation
Comdata Corporation is a leading business-to-business provider of innovative electronic payment solutions. As an issuer and a processor, the company provides fleet, corporate payment, virtual card, and prepaid solutions to over 30,000 customers. There are more than seven million Comdata Cards, enabling more than $31 billion in transactions annually. Comdata captures and reports detailed transaction data, giving customers unprecedented control over their expenses. Founded in 1969 and headquartered in Brentwood, Tennessee with more than 1,000 employees in the United States and Canada, Comdata is a wholly-owned subsidiary of Ceridian Corporation. For more information, visit www.comdata.com.
About ControlScan
Headquartered in Atlanta, Georgia, ControlScan provides Payment Card Industry (PCI) compliance solutions that fit the specific needs of small- to medium-sized merchants. The company helps simplify PCI compliance and reduce risk for acquirers by achieving high PCI compliance rates for their merchants. As a market leader in PCI compliance, ControlScan offers its acquirer partners the unique benefits of an exclusive focus on servicing Level 4 merchants, programs that work based on the needs of each acquirer and a track record of success in achieving high PCI compliance rates. For more information about ControlScan and its solutions, visit www.controlscan.com.
Contact:Ray Grovergrove@convey.com763-235-5739
SOURCE Convey Compliance Systems
Copyright (C) 2011 PR Newswire. All rights reserved
ALDA Receives Registration for Hydrocortisone Ointment(ccnm)
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 8, 2011) -ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCQB:APCSF) (the "Company" or"ALDA") announces that Natural Product Number ("NPN") 80026033 has been issuedfor a 0.5% hydrocortisone (0.5% HC) ointment. The Company is authorized to sellthis product in Canada for temporary relief of minor skin irritations, rashes,itching and redness due to eczema, insect bites, poison ivy and other irritatingplants; contact dermatitis caused by soaps, detergents, cosmetics, jewellery andother materials that irritate the skin; seborrheic dermatitis and psoriasis.
Typically, skin conditions of these types (which affect over 75% of Canadianadults at one time or another) begin as an inflammatory condition, but are oftenworsened or prolonged by secondary infection with bacteria or fungi (such as thefungi that causes athlete's foot). The combination of an effectiveanti-microbial product (such as the T36® formulation) withan anti-inflammatory agent (such as 0.5% hydrocortisone) would address thiscommon medical condition more effectively and make treatment recommendationsmore straightforward for the health care provider and much easier to carry outfor the patient. This innovative combination of an anti-microbial andanti-inflammatory therapy (avoiding the need to apply separate products to treata single condition) represents an important step forward in the non-prescriptiontherapeutic market. It is also consistent with the current approach favoured bya number of health providers encouraging Canadians to take charge in a positiveway of their own care. Obtaining registration of a hydrocortisone ointment is afirst step for the Company in bringing this approach to market.
About ALDA Pharmaceuticals Corp.
ALDA is focused on the development of infection-control therapeutics derivedfrom its patented T36® technology. The Company trades onthe TSX Venture Exchange under the symbol APH.
Terrance G. Owen, Ph.D., MBA, President & CEO
ALDA Pharmaceuticals Corp.
Call me a sucker; but I couldn't resist; so I bought a few thousand just in case! :)
Arbitration Panel Issues Declaration That Goldbrook Entitled to 25% Interest in Nunavik Nickel Project
7/20/2011 8:17:40 PM - NFD
VANCOUVER, BRITISH COLUMBIA, Jul 20, 2011 (Marketwire via COMTEX News Network) --
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
As Goldbrook Ventures Inc. (TSX VENTURE:GBK) ("Goldbrook") announced on October 20, 2010, Goldbrook commenced an arbitration (the "Arbitration") pursuant to the Shareholder, Joint Bid and Operating Agreement between Jilin Jien Nickel Industry Co., Ltd., Jien International Investment Ltd. and Jien Canada Mining Ltd., dated August 6, 2009 (the "Shareholders Agreement") against Jilin Jien Nickel Industry Co., Ltd. and its affiliates ("Jilin Jien").
The Arbitration was in respect of Jilin Jien's purported issuance of 494 voting common shares of Jien Canada Mining Ltd. ("Jien Canada") that would reduce Goldbrook's percentage of voting shares, and consequently Goldbrook's interest in the Nunavik Nickel Project, from 25% to 4.21% (the "Dilution"). Today the Arbitration Tribunal issued a partial final award in respect of the Arbitration.
The Arbitration Tribunal found that Goldbrook is entitled under the Shareholders Agreement to be the holder of 25% of the voting shares of Jien Canada and that the issuance of 494 voting shares that would have effected the Dilution was not authorized by, and was contrary to, the Shareholders Agreement.
The Tribunal further directed that if Goldbrook intends to seek an award directing the steps to be taken to restore its 25% shareholding beyond the declarations made in the Award that the Tribunal requires submissions from the parties on that issue. The Tribunal has reserved its jurisdiction to decide all matters relating to costs until any further submissions have been made.
Goldbrook intends to pursue any further steps necessary in order to restore its 25% interest in the Nunavik Nickel Project.
About Goldbrook
Goldbrook Ventures is engaged in the exploration and development of Nickel-Copper-Platinum Group Element sulphide deposits - a class of mineral deposit that, due to its polymetallic nature, has an advantage of protection against individual metal price cycles and has strong long term supply-demand fundamentals. Goldbrook's quest for discovery is focused in the Raglan District of Northern Quebec, a district that hosts Xstrata's Raglan operations, arguably one of the world's most profitable nickel-copper-PGE mines.
Goldbrook's Raglan project is a joint venture with Jilin Jien Nickel Industry Co., Ltd. ("Jilin Jien") under which Goldbrook and Jilin Jien each hold a fifty percent interest in the Goldbrook properties. Goldbrook is also a shareholder in Jien Canada Mining Ltd., owner of the Nunavik Nickel Project.
ON BEHALF OF THE BOARD:
David Baker, Chairman and Director
Cautionary Note Regarding Forward-Looking Statements
Certain of the statements made herein may contain forward-looking statements or information within the meaning of Canadian securities laws and the applicable securities laws of the United States. Such forward looking statements or information include, but are not limited to, statements or information with respect to Goldbrook's plan for future exploration and development of its properties and the results of any arbitration proceedings against Jilin Jien and others.
Forward-looking statements or information are based on a number of estimates and assumptions and are subject to a variety, of risks and uncertainties, which could cause actual events or results to differ from those reflected in the forward-looking statements or information. Should one or more of these risks and uncertainties materialize, or should underlying estimates and assumptions prove incorrect, actual results may vary materially from those described in forward looking statements or information. Factors related to such risks and uncertainties, and underlying estimates and assumptions include, among others, the following: the ability of Goldbrook to advance development of its properties; price volatility of nickel and other metals; impact of any hedging activities, including margin limits and margin calls; discrepancies between actual and estimated production, between actual and estimated resources, and between actual and estimated metallurgical recoveries; mining operational risk; regulatory restrictions, including environmental regulatory restrictions and liability; risks of sovereign investment; speculative nature of mineral exploration; defective title to mineral claims or property, litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; technological or operational difficulties or inability to obtain permits encountered in connection with exploration activities; and labour relations matters. Accordingly, undue reliance should not be placed on forward looking statements or information. We do not expect to update forward-looking statements or information continually as conditions change, except as may be required by law.
SOURCE: Goldbrook Ventures Inc.
Goldbrook Ventures Inc. David Baker Chairman and Director 604-683-8083 or Toll Free: 1-888-488-9884 604-683-8087(FAX) www.goldbrookventures.com
Copyright (C) 2011 Marketwire. All rights reserved.
Hey Janet, did you see the news on GBK this morning? We should finally see some good things happening from here on in. Time to get back out in the sun. Have a good day.
Almost tempted to buy some more.
That and the share structure of the new company wil be discussed in thier next press release. :)
News out on OTGI!
No problem, I'm usually too quick with the mouse as well! :)
What does anyone think of VTSI? I got out when they announced the RS. Now that they have changed their minds, for now, the pps has been rebounding. Thinking of getting back in short term.
I just finally got filled at 0.16. Now we wait and see if something serious happens here.
MultiCell Technologies receives European patent for cancer therapies
Apr 26, 2011 (Datamonitor via COMTEX News Network) --
MultiCell Technologies, Inc., a clinical-stage bio-pharmaceutical company, has received a European patent covering certain of its therapeutic agents for the treatment of cancer.
MultiCell has created a new class of recombinant antibody therapeutics which redirect the immune response to specific cancer targets corresponding to the peptides engrafted onto the recombinant antibody. Such compositions are able to transform seemingly ineffective peptides into potent antibody therapeutics with a different mechanism of action compared to that of conventional antibody therapeutics currently in clinical use.
These recombinant antibody therapeutics not only produce a potent immune response, but also stimulate the generation of cytolytic cells, and Interferon-gamma and Interleukin-2 producing T-cells. When coupled with MultiCell's dsRNA therapeutics, this new class of recombinant antibody therapeutics has been shown in animal models to eradicate cancer and generate immune protection against the reoccurrence of malignant tumors.
"We are very pleased that the European Patent Office has decided to grant us a patent covering our novel compositions and method for the treatment of cancer as well as for the treatment of infectious disease," stated Jerry Newmin, Chairman and CEO of MultiCell Technologies. "Our technology uses the antibody molecule as a platform to better present a peptide to immune cells thereby increasing the overall immune response to the peptide," Mr Newmin added.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon
Copyright (C) 2011 Datamonitor. All rights reserved
UMJ has nice volume today on a relatively down day again on the Venture exchange. Made money on this one in the past. Thinking of jumping in again.
Retrace, consolidation and then upward movement again. Excellent long term hold in my book and playing it short term at the same time may be a little difficult; but I plan on trying to do both.
Took a position in it this morning on fundamentals and gut feeling and to see how accurate my chart reading was on it on Friday after the close. :)
First of all thank you for your reply. Secondly I am very aware that this is probably a very good long term hold and I will take a long position probably next week some time. Also I usually trade with gut feeling and public sentiment as well. I have more than one trading account so I was just trying to pick your brain on the chart thing to see if I was reading this one right. Trying to wrap my head around candlestick patterns and such for some short term trades.
I'm not getting any younger and would like to retire soon and do more travelling. I bought a travel trailer last year and am trading it all in on an RV. Air travel is for Europe and other places you can't drive to yet. I prefer to see North and South America slowly with one foot on the gas pedal and the window rolled down. I’m a hippy from the late sixties early seventies era. Anyway time to go out and enjoy the sunshine before the day is done. Have a good day and happy trading to all next week.
Yes Janet, good article and believe me when I say I will not wait long to take a long position as I think this one could put some serious cash in my retirement fund at some point. Although with stocks like this one, that may have large swings in share price for awhile, I like to have a short term position as well. Have a good night. :)
Surfin, I'm not great at reading charts; but would you not say that a serious reversal with CTSO is imminent on Monday? Just trying to learn something else to help me with short term trades. I will eventually lock in some long term shares in this one again soon however.
SurfinNj, yes I always liked their product and what it could be capable of. Also if they can get approvals in the US then yes it could be a multi bagger long term. For now I think I will continue to play it short term. Looks like the day traders may be starting to bail. I will have to try and keep an eye on it, or maybe just put in a low ball number if I can’t. Have a good day.
I can’t remember where you said you lived as you where talking about storms, just wondering.
Yes I am. Put in a sell at 0.35, as I had to go out, and got filled. I have made money on this one in the past; but it has been awhile. Hopefully it retraces and I can get back in at a lower price. If not, I’ll decide what to do as time goes by. Have a good day. Have to open a bottle of wine and fire up the barbecue to celebrate. :)
Not sure if anyone has heard or is in this one, but CTSO had some good news this morning. I have had this one for awhile and have been waiting for news such as this for some time now.
Investment Industry Regulatory Organization of Canada - Trading Halt - Stem Cell Therapeutics Corp. - SSS
VANCOUVER, Mar 18, 2011 (Canada NewsWire via COMTEX News Network) --
The following issues have been halted by Investment Industry Regulatory Organization of Canada (IIROC):
Issuer Name: Stem Cell Therapeutics Corp. TSX-V Ticker Symbol: SSS Time of Halt: 9:58 E.S.T. Reason for Halt: Company Request Pending News
To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/March2011/18/c4329.html
SOURCE: Investment Industry Regulatory Organization of Canada (IIROC)
SOURCE: Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions
<p>IIROC Inquiries (416) 646-7299 - *Please note that IIROC is not able to provide any additional information regarding a specific trading halt. Information is limited to general enquiries only.</p>
Copyright (C) 2011 CNW Group. All rights reserved.
I doubt very much that anyone will buy into this news except for some day trading. I can't wait to check Canadian Insider to see if any of our friends at Alda bought or sold any of the shares traded today. That would tell you all you need to know about their intentions. This deal has got to go through this time or this company is toast!
He must realize that if he fails again that any confidence left in this company will be completely eroded away. This deal, in my opinion, is a make or break for Alda. All we can do is hope that he did his homework this time. We can also hope for the announcement to come in as a done deal and the share price to rise dramatically on that and a couple of other quick NRs before a PP.
I’m not trying to be condescending or anything; but I only trade pink sheets and otcbb stocks as a hobby, as you rarely make any serious money on any of them. I have been lucky, but it is rare. I prefer the TSX, TSX.v, NYSE and the Nasdaq when trying to make serious money.
That article is way too technical for someone with the intellect that you believe I have. Besides, my attention span is not what it used to be. :)
Ouch! Apparently we are on to something that doesn't sit well with someone! :)
Those where some pretty entertaining posts joshkocses. Also I’m starting to believe you may be on to something that might be of interest to others.
OT: SAEI on another big run on news! :)
The weekend is looking better by the minute and thank you for the tip! So far the risk has been worth it. Only time will tell if we can retire to the Riviera on this one! :) Ok 0.67, so do I hear 0.75! :)
I know I do!!!! :)
OT: 0.60 it is! Do I hear 0.65! :)
OT: It's early yet, back up over 0.06! :)
This was an answer to an email I sent a few weeks ago. Got lost in my junk folder. Not much to say but at least I received a reply.
Unfortunately the share price is struggling. We are working on new avenues of revenue to help increase sales and the bottom line. The marketplace is overloaded with hand sanitizer right now (left over inventory from H1N1 scare) but fortunately we have numerous other infection control products to sell. We are certainly lacking on the news front over the last couple of months but continue to move forward on the therapeutic side of things.
Thank you for remaining as a shareholder. We continue to work on the share price and hopefully we will see some improvement over the next few months.
Scott Young
IIROC issues proposal for Single-Stock Circuit Breakers and invites public comment
TORONTO, Nov. 18 /CNW/ - The Investment Industry Regulatory Organization of Canada (IIROC) has issued for public comment a proposal to implement single-stock circuit breakers to address rapid, significant and unexplained price movement in a security that calls into question whether there is a "fair and orderly" market for that security. The proposal builds on the approach followed by IIROC when instituting coordinated regulatory halts across all Canadian marketplaces that trade a particular security.
Under IIROC's proposal, single-stock circuit breakers would apply to all securities listed on an exchange in Canada, including securities inter-listed in Canada and the U.S. When a stock price increases or decreases past a certain threshold, the circuit breaker would trigger a trading halt to provide a pause.
The proposed halt would last five minutes for TSX-listed shares, with the possibility of an extension in the case of a severe order imbalance. The proposed halt for stocks listed on the TSX-Venture and CNSX exchanges is 10 minutes to account for lower levels of liquidity.
Shortly after the May 6 Flash Crash, the Canadian Securities Administrators and IIROC together announced they had begun a comprehensive analysis of the events of the crash, including a review of the "appropriateness of the existing circuit breaker policy." During the crash, markets in the US and Canada experienced extreme volatility, with some stocks quickly experiencing dramatic price declines and rallies.
Under the Universal Market Integrity Rules (UMIR), IIROC has the authority to delay, halt or suspend trading at any time where it is considered appropriate and in the interest of a fair and orderly market. The regulatory halt may apply market-wide or to particular securities. This allows for the imposition of manual halts to address unexplained price movements in a single security. However, current practice is not adequate where there is a need to halt trading in multiple securities across multiple marketplaces, all in a short window of time.
The thresholds under the proposal distinguish between more liquid and less liquid securities. The proposed thresholds are:
•For TSX-listed securities, a halt would be initiated where a stock's price increases or decreases by at least 10 per cent or 10 trading increments, whichever is greater, over a five-minute period.
•For securities listed on the TSX-V or CNSX, a halt would be initiated where a stock's price increases or decreases by at least 20 per cent or 20 trading increments, whichever is greater, over a 10-minute period.
The circuit breakers would be in effect from 9:50 am to 3:40 pm ET.
The Single-Stock Circuit Breaker Proposal is intended to operate as part of a multi-tiered approach for controlling short-term, unexplained price volatility:
I. The first set of controls is at the market participant level where, under UMIR, firms are required to comply with their existing trade supervision obligations.
II. The second set of controls would be effective marketplace volatility controls with consistent objectives across marketplaces.
III. The single-stock circuit breaker would represent the third level of controls.
Both market participant obligations and marketplace level controls should be designed to detect 'erroneous orders' prior to execution. Each of the above-noted elements plays an important role in the overall control framework designed to mitigate the risks associated with unexplained short-term price movement and to promote fair and orderly markets.
The proposal calls for a three-stage process consisting of initial consultation and development, implementation and review/evaluation.
Public Comment Period: The proposal is being issued for a 60-day comment period.
Once comments are received from the public, marketplace participants and the Canadian Securities Administrators, IIROC will review the comments and, as appropriate, revise the Single-Stock Circuit Breaker Proposal. Comments should be directed to:
Timothy Ryan,
Director, Market Regulation Policy,
Investment Industry Regulatory Organization of Canada,
Suite 900 145 King Street West, Toronto, Ontario. M5H 1J8
Fax: 416.646.7265 e-mail: tryan@iiroc.ca
IIROC issues proposal for Single-Stock Circuit Breakers and invites public comment
TORONTO, Nov. 18 /CNW/ - The Investment Industry Regulatory Organization of Canada (IIROC) has issued for public comment a proposal to implement single-stock circuit breakers to address rapid, significant and unexplained price movement in a security that calls into question whether there is a "fair and orderly" market for that security. The proposal builds on the approach followed by IIROC when instituting coordinated regulatory halts across all Canadian marketplaces that trade a particular security.
Under IIROC's proposal, single-stock circuit breakers would apply to all securities listed on an exchange in Canada, including securities inter-listed in Canada and the U.S. When a stock price increases or decreases past a certain threshold, the circuit breaker would trigger a trading halt to provide a pause.
The proposed halt would last five minutes for TSX-listed shares, with the possibility of an extension in the case of a severe order imbalance. The proposed halt for stocks listed on the TSX-Venture and CNSX exchanges is 10 minutes to account for lower levels of liquidity.
Shortly after the May 6 Flash Crash, the Canadian Securities Administrators and IIROC together announced they had begun a comprehensive analysis of the events of the crash, including a review of the "appropriateness of the existing circuit breaker policy." During the crash, markets in the US and Canada experienced extreme volatility, with some stocks quickly experiencing dramatic price declines and rallies.
Under the Universal Market Integrity Rules (UMIR), IIROC has the authority to delay, halt or suspend trading at any time where it is considered appropriate and in the interest of a fair and orderly market. The regulatory halt may apply market-wide or to particular securities. This allows for the imposition of manual halts to address unexplained price movements in a single security. However, current practice is not adequate where there is a need to halt trading in multiple securities across multiple marketplaces, all in a short window of time.
The thresholds under the proposal distinguish between more liquid and less liquid securities. The proposed thresholds are:
•For TSX-listed securities, a halt would be initiated where a stock's price increases or decreases by at least 10 per cent or 10 trading increments, whichever is greater, over a five-minute period.
•For securities listed on the TSX-V or CNSX, a halt would be initiated where a stock's price increases or decreases by at least 20 per cent or 20 trading increments, whichever is greater, over a 10-minute period.
The circuit breakers would be in effect from 9:50 am to 3:40 pm ET.
The Single-Stock Circuit Breaker Proposal is intended to operate as part of a multi-tiered approach for controlling short-term, unexplained price volatility:
I. The first set of controls is at the market participant level where, under UMIR, firms are required to comply with their existing trade supervision obligations.
II. The second set of controls would be effective marketplace volatility controls with consistent objectives across marketplaces.
III. The single-stock circuit breaker would represent the third level of controls.
Both market participant obligations and marketplace level controls should be designed to detect 'erroneous orders' prior to execution. Each of the above-noted elements plays an important role in the overall control framework designed to mitigate the risks associated with unexplained short-term price movement and to promote fair and orderly markets.
The proposal calls for a three-stage process consisting of initial consultation and development, implementation and review/evaluation.
Public Comment Period: The proposal is being issued for a 60-day comment period.
Once comments are received from the public, marketplace participants and the Canadian Securities Administrators, IIROC will review the comments and, as appropriate, revise the Single-Stock Circuit Breaker Proposal. Comments should be directed to:
Timothy Ryan,
Director, Market Regulation Policy,
Investment Industry Regulatory Organization of Canada,
Suite 900 145 King Street West, Toronto, Ontario. M5H 1J8
Fax: 416.646.7265 e-mail: tryan@iiroc.ca
This is from another board. Posted yesterday by KayDay.
Tonight's call was very interesting and positive. It was nice to be able to ask questions and get comprehensive answers... though it was hard to hear everything with people joining and leaving every couple of minutes. I did walk away with a few points. Note: I couldn't take notes because I was driving so please feel free to correct any errors... I will leave details to others.
1. They have a plan and an offer of intent on the table. Alan couldn't name the company but gave details about what the offer entailed. He only just got the offer after the release on Friday and stressed that this group approached SSS. There is interest and they would partner sooner rather than later. I will leave it to someone else who took notes to explain the details.
2 They are acutely aware of the financial state of the company but have many options that will finance all of our trials including stroke. I asked about dilution and they said that it is always an option but at a higher sp... he went on to say that with the current plan there may not be a need to raise any more money and therefore no need to dilute. In other words the current plan could give them all they need to continue.
3. TBI trials are accounted for financially and should have their first patient by year end with the trial lasting 6-8 months. The US army is very interested as is their contact in the States who has himself suffered from TBI. This is something they are very excited about.
4. The end of phase II meeting is a formality and they are confident that they will move forward. The FDA doesn't grant these meetings to everyone. SSS had to submit material before hand for the FDA to allow a meeting, the fact that we have a date set is very positive. They did not have to ask for a meeting but wanted to make sure that they did everything by the book and wanted to check this off their list. With the current results the FDA should be happy and SSS has someone on their team in place who has dealt extensively with the FDA who will accompany them and be present at the meeting.
5. I asked Alan if SSS was under the impression that everyone in the stroke trial would have OT and he said YES. They were very surprised to learn that not everyone got OT as a standard treatment protocol. Our drug without OT is like steroid use without lifting weights.
6. Lastly, why did Dean Peterson buy 10% of the company... he had shares before the drop and has followed the company for a long time. When the news in May came out and he heard all the negative information and feedback, he felt that it didn't add up. Then reading the results, he didn't find them them that bad and decided to take a closer look... with DD he decided to buy more shares and wanted to get involved formally with the company.
These are the points that stuck with me and some of the questions I asked, I'm sure I have forgotten lots so I will depend on others to share. This is all from memory.
All in all, I walked away excited and feel like my decision to keep my shares and buy more was a good one. They have a solid team in place committed to treat this like a business with the priority being the product and the valuation. I only wish that they would release all this to the public in a well worded press release... what I heard tonight is nothing like the releases we have been getting. In the end, I agree with Alan ... for where we are in our trial, with the successes we have achieved, and the drugs and IP we have... SSS is grossly undervalued.
OT - Thank you Janet; yes there is a lot of excitement on that board. I've been in for some time now. My average price is 0.06 and holding long! Getting in now is probably still a good deal for you in my opinion. Many more NRs coming soon! :)
OT - Does that stand for "Driving While Intoxicated" and is this latest investment a 1 year or 5 year plan! :)